Sweden Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

1.1 List of Figures
1.2 List of Tables

2.1 Executive Summary
2.2 Key Highlights: Facts About the Sweden Healthcare Market
2.3 Key Highlights: Healthcare Startups in Sweden
2.4 Key Events: Sweden Healthcare Timeline, 2016-22
2.5 Key Events: Sweden Pharmaceutical Market
2.6 Key Events: M&As, VC, and PE Deals, Global Pharmaceutical Market, 2021-22
2.7 Key Events: Top Completed Deals by Value, 2021-22
2.8 Country Profile, Sweden, 2021

3.1 Pharmaceutical Market - Overview
3.2 Pharmaceutical Market - Exports
3.3 Pharmaceutical Market - Imports
3.4 Pharmaceutical Market - Supply Channels, Sweden
3.5 Pharmaceutical Market - Market Segments
3.6 Pharmaceutical Market - Market Segments, Generics, Sweden
3.7 Pharmaceutical Market - Market Segments, Biologics and Biosimilars, Sweden
3.8 Pharmaceutical Market - Market Segment, Over-the-Counter Medicines, Sweden
3.9 Pharmaceutical Market - Major Therapeutic Areas, Sweden
3.10 COVID-19 Epidemiology, Sweden
3.11 COVID-19 Impact and Developments in the Healthcare Market, Sweden
3.12 COVID-19 Clinical Trials Landscape, Sweden
3.13 Pharmaceutical Market - Major Players

4.1 Medical Device Market - Overview
4.2 Medical Devices Market - Major Players

5.1 Drivers
5.2 Barriers

6.1 Deal Analysis: Pharmaceutical Market, Sweden, 2020-22
6.2 Deal Analysis: Medical Devices Market, Sweden, 2020-22

7.1 Healthtech Landscape, Sweden
7.2 Healthtech Deals Landscape, Sweden
7.3 Key Healthtech Deals, Sweden
7.4 Adoption of Technology in Healthcare, Sweden
7.5 Digital Statistics, Sweden
7.6 Major Digital Regulations, Sweden
7.7 Digital Health - Benefits and Risks, Sweden

8.1 Overview of Healthcare System, Sweden
8.2 Reimbursement Landscape, Sweden
8.3 Overview of Insurance Providers, Insurance, Sweden
8.4 Healthcare Spending and Prescription Drug Price Trends, Sweden
8.5 Pricing Policies, Sweden
8.6 Market Access: Key Events Timeline, Taiwan, 2010-24
8.7 Regulatory Landscape, Sweden
8.7.1 Marketing Authorization for Pharmaceutical Products, Sweden
8.7.2 Marketing Authorization for Biosimilars, Sweden
8.7.3 Marketing Authorization for Medical Devices, Sweden
8.7.4 Pharmaceutical and Medical Device Establishment Regulations, Sweden
8.7.5 Intellectual Property Rights, European Patent, Sweden
8.7.6 Intellectual Property Rights, European Unitary Patent, Sweden
8.7.7 Intellectual Property Rights, Patents, Sweden
8.7.8 Intellectual Property Rights, Trademark, Sweden
8.7.9 Clinical Trial Regulation, Sweden
8.7.10 Pharmaceutical Clinical Trials Landscape, Sweden
8.7.11 Medical Devices Clinical Trials Landscape, Sweden
8.7.12 Pharmaceutical Export and Import, Sweden
8.7.13 Pharmaceutical Advertising Regulations, Sweden
8.7.14 Pharmaceutical Licensing Regulations, Sweden
8.7.15 Labeling and Packaging Regulations, Sweden

9.1 Swedish Healthcare Policy Highlights
9.2 Healthcare Facilities, Sweden
9.3 Life Expectancy and Immunization Rate, Sweden
9.4 Environmental Health, Sweden
9.5 Healthcare Personnel, Sweden
9.6 Disease Burden, Sweden
9.7 Healthcare Expenditure, Sweden
9.8 Healthcare Spending Components and Pharmaceutical Spending, Sweden

13.1 Research Methodology
13.1.1 Coverage
13.1.2 Secondary Research
13.1.3 Forecasts
13.2 Bibliography
13.3 About the Publisher
13.4 Contact the Publisher
13.5 Disclaimer

Table 1: Approved biosimilars, EU, 2020-21
Table 2: Likelihood of approval, EU
Table 3: COVID-19 indicators, global and Sweden, 2022
Table 4: Authorized COVID-19 vaccines, Sweden, 2020-22
Table 5: Marketed COVID-19 IVD products, Sweden, 2020-22
Table 6: Marketed COVID-19 IVD products, Sweden, 2020-22
Table 7: Medical devices market, major segments ($M), Sweden, 2021
Table 8: Hospital supplies market, revenue ($M) and market share (%) of major companies, Sweden, 2021
Table 9: Cardiovascular devices market, revenue ($M) and market share (%) of major companies, Sweden, 2021
Table 10: Orthopedic devices market, revenue ($M) and market share (%) of major companies, Sweden, 2021
Table 11: General surgery devices market, revenue ($M) and market share (%) of major companies, Sweden, 2021
Table 12: Wound care management market, revenue ($M) and market share (%) of major companies, Sweden, 2021
Table 13: Role of the healthcare authorities, Sweden, 2022
Table 14: Benefits associated with SSIA, Sweden, 2021
Table 15: Pricing of medicines at different levels, Sweden, 2022
Table 16: MA application type and fees, Sweden, 2022
Table 17: MA annual fees, Sweden, 2022
Table 18: Medical devices registration fees, Sweden, 2022
Table 19: Trademark fees, Sweden, 2022
Table 20: Advertising regulations, Sweden, 2022
Table 21: Advertising of pharmaceutical products through other mass media, Sweden, 2022
Table 22: Label of outer packaging and medicine containers, Sweden, 2022
Table 23: Label of pharmaceutical blister, Sweden, 2022
Table 24: Label of small pharmaceutical packaging, Sweden, 2022
Table 25: Trade fairs, Sweden, 2022

Figure 1: Pharmaceutical market, revenue ($B and SEKB), Sweden, 2015-22
Figure 2: Medical devices market, revenue ($B), Sweden, 2016-22
Figure 3: Healthcare start-ups in Sweden, 2022
Figure 4: Country profile, Sweden, 2021
Figure 5: Pharmaceutical market, revenue ($B and SEKB), Sweden, 2015-21
Figure 6: Pharmaceutical market, forecast revenue ($B and SEKB), Sweden, 2022-26
Figure 7: Pharmaceutical exports ($B), Sweden, 2013-21
Figure 8: Top export partners, Sweden, 2021
Figure 9: Pharmaceutical imports ($B), Sweden, 2013-21
Figure 10: Top import partners, Sweden, 2021
Figure 11: Number of outpatient pharmacies, Sweden, 2013-20
Figure 12: Pharmaceutical supply channel, Sweden, 2022
Figure 13: Major generic drug companies, Sweden, 2022
Figure 14: OTC medicines market, revenue ($B), Sweden, 2013-22
Figure 15: OTC medicines market, major categories ($M), Sweden, 2021
Figure 16: Major therapeutic areas by pharmaceutical consumption (DDD per 1,000 inhabitants per day), Sweden, 2019-21
Figure 17: Pharmaceutical market, sales of patented drug products (by major therapeutic class), Sweden, 2021
Figure 18: COVID-19 (cumulative number of cases), Sweden, 2020-22
Figure 19: COVID-19 (cumulative number of deaths), Sweden, 2020-22
Figure 20: COVID-19 Government Stringency Index, Sweden, 2020-22
Figure 21: COVID-19 Containment and Health Index, Sweden, 2020-22
Figure 22: COVID-19 vaccine dose administration (number of administered vaccine doses), Sweden, 2020-22
Figure 23: COVID-19 clinical trials sponsors by count, Sweden, 2020-22
Figure 24: COVID-19 clinical trials count by phase, Sweden, 2020-22
Figure 25: COVID-19 clinical trials count by trial status, Sweden, 2020-22
Figure 26: Medical devices market, revenue forecast ($B), Sweden, 2016-21
Figure 27: Medical devices market, revenue forecast ($B), Sweden, 2022-27
Figure 28: Medical devices market, major segments (%), Sweden, 2021
Figure 29: Hospital supplies market, revenue ($M), Sweden, 2017-27
Figure 30: Hospital supplies market, market share of major players (%), Sweden, 2021
Figure 31: Cardiovascular devices market, revenue ($M), Sweden, 2017-27
Figure 32: Cardiovascular devices market, market share of major players (%), Sweden, 2021
Figure 33: Orthopedic devices market, revenue ($M), Sweden, 2017-27
Figure 34: Orthopedic devices market, market share of major players (%), Sweden, 2021
Figure 35: General surgery devices market, revenue ($M), Sweden, 2017-27
Figure 36: General surgery devices market, market share of major players (%), Sweden, 2021
Figure 37: Wound care management market, revenue ($M), Sweden, 2017-27
Figure 38: Wound care management market, market share of major players (%), Sweden, 2021
Figure 39: Diagnostic market, revenue ($M), Sweden, 2016-21
Figure 40: Diagnostic market, revenue ($M), Sweden, 2022-27
Figure 41: Medical devices market, revenue ($B) of major companies, Sweden, 2021
Figure 42: Deals value and deal count, pharmaceutical market, Sweden, 2020-22
Figure 43: Deals value and deal count, subtypes, pharmaceutical market, Sweden, 2020-22
Figure 44: Deals value and deal count, quarterly, pharmaceutical market, Sweden, 2020-22
Figure 45: Top therapy areas by deal value ($M), pharmaceutical market, Sweden, 2020-22
Figure 46: PE deals by quarter (by value and by number), pharmaceutical market, Sweden, 2020-22
Figure 47: Top therapy areas by deal count, pharmaceutical market, Sweden, 2020-22
Figure 48: M&A deals by quarter (by value and by number), pharmaceutical market, Sweden, 2020-22
Figure 49: Deals value and deal count, medical devices market, Sweden, 2020-22
Figure 50: Deals value and deal count, quarterly, medical devices market, Sweden, 2020-22
Figure 51: Deals value and deal count, subtypes, medical devices market, Sweden, 2020-22
Figure 52: Top equipment sectors by deal value ($M), medical devices market, Sweden, 2020-22
Figure 53: Top equipment sectors by deal count, medical devices market, Sweden, 2020-22
Figure 54: M&A deals by value and by number (bi-annually), medical devices market, Sweden, 2020-22
Figure 55: PE deals by quarter, by value and by number (bi-annually), medical devices market, Sweden, 2020-22
Figure 56: Deals value ($B), HealthTech, Sweden, 2020-22
Figure 57: Deal count (number of deals), HealthTech, Sweden, 2020-22
Figure 58: GDPR compliance checklist, EU, 2022
Figure 59: Organization of healthcare system, Sweden, 2022
Figure 60: Drug funding and reimbursement approval process, Sweden, 2022
Figure 61: OOP expenditure (% of current expenditure on health), Sweden, 2013-20
Figure 62: Pharmaceutical price index, Sweden, 2014-22
Figure 63: Medical Products Agency (MPA), organization chart, Sweden, 2022
Figure 64: Drug authorization procedures, EU, 2022
Figure 65: Centralized procedure, Sweden, 2022
Figure 66: Decentralized procedure, Sweden, 2022
Figure 67: Mutual recognition procedure, Sweden, 2022
Figure 68: New drug approval process, Sweden, 2022
Figure 69: Marketing authorization for pharmaceutical products, Sweden, 2022
Figure 70: Conformity assessment of Class I medical devices, EU, 2022
Figure 71: Conformity assessment of Class IIa medical devices, EU, 2022
Figure 72: Conformity assessment of Class IIb medical devices, EU, 2022
Figure 73: Conformity assessment of Class III medical devices, EU, 2022
Figure 74: European patent approval process, EU, 2022
Figure 75: Unitary patent approval process, EU, 2022
Figure 76: Patent approval process, Sweden, 2022
Figure 77: Clinical trial process, Sweden, 2022
Figure 78: Pharmaceutical clinical trials count by trial status, Sweden, 2020-22
Figure 79: Pharmaceutical clinical trials count by phase, Sweden, 2020-22
Figure 80: Pharmaceutical clinical trials count by therapy areas, Sweden, 2020-22
Figure 81: Top five pharmaceutical clinical trials sponsors by count, Sweden, 2020-22
Figure 82: Medical devices clinical trials count by trial status, Sweden, 2020-22
Figure 83: Medical devices clinical trials count by indication, Sweden, 2020-22
Figure 84: Medical devices clinical trials count by therapeutic areas, Sweden, 2020-22
Figure 85: Top five medical devices clinical trials sponsors by count, Sweden, 2020-22
Figure 86: Number of hospital beds (per 1,000 population), Sweden, 2013-21
Figure 87: Number of diagnostic equipment units (per million population), Sweden, 2015-21
Figure 88: Immunization coverage (%), Sweden, 2013-20
Figure 89: Life expectancy at birth (years), Sweden, 2013-21
Figure 90: CO2 emissions (Mt CO2 per capita), Sweden, 2013-21
Figure 91: PM2.5 (µg per m3), Sweden, 2013-21
Figure 92: Physicians (per 1,000 population), Sweden, 2013-21
Figure 93: Pharmacists (per 1,000 population), Sweden, 2011-21
Figure 94: Nurses (per 1,000 population), Sweden, 2013-21
Figure 95: Dentists (per 1,000 population), Sweden, 2013-21
Figure 96: Major causes of male mortality (per 100,000 population), Sweden, 2021
Figure 97: Major causes of female mortality (per 100,000 population), Sweden, 2021
Figure 98: Healthcare expenditure as percentage of GDP (%), Sweden, 2013-21
Figure 99: Public-private share (% of total health spending), Sweden, 2013-21
Figure 100: Healthcare expenditure components by function (% of total health expenditure), Sweden, 2020
Figure 101: Pharmaceutical spending ($ per capita), Sweden, 2013-20